Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication

Clin Infect Dis. 2010 Apr 15;50(8):1192-7. doi: 10.1086/651419.

Abstract

Consecutive missed doses may differentially impact the efficacy of antiretroviral therapy associated with the use of a nonnucleoside reverse-transcriptase inhibitor (NNRTI) and a ritonavir-boosted protease inhibitor (PI). In a cohort of 72 subjects receiving a boosted PI, average adherence to dosage was a better predictor of human immunodeficiency virus (HIV) replication than was the duration or frequency of treatment interruption. In contrast with an NNRTI, consecutive missed doses of a boosted PI did not emerge as a major risk factor for HIV replication.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use*
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / virology*
  • HIV Protease Inhibitors / therapeutic use*
  • Humans
  • Male
  • Medication Adherence / statistics & numerical data*
  • Middle Aged
  • RNA, Viral / blood*
  • Viral Load*

Substances

  • Anti-HIV Agents
  • HIV Protease Inhibitors
  • RNA, Viral